Published in J Ethnopharmacol on September 28, 2012
Efficacy and safety of a herbal mixture (Viron® tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study. Drug Des Devel Ther (2015) 0.83
Identification of luteolin as enterovirus 71 and coxsackievirus A16 inhibitors through reporter viruses and cell viability-based screening. Viruses (2014) 0.83
In vitro antiviral activity of plant extracts from Asteraceae medicinal plants. Virol J (2013) 0.81
A Complex Multiherbal Regimen Based on Ayurveda Medicine for the Management of Hepatic Cirrhosis Complicated by Ascites: Nonrandomized, Uncontrolled, Single Group, Open-Label Observational Clinical Study. Evid Based Complement Alternat Med (2015) 0.78
Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors. Drug Des Devel Ther (2015) 0.77
Ethnopharmacological Significance of Eclipta alba (L.) Hassk. (Asteraceae). Int Sch Res Notices (2014) 0.76
The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors. J Med Chem (2013) 0.76
Comparative hair restorer efficacy of medicinal herb on nude (Foxn1nu) mice. Biomed Res Int (2014) 0.76
Wedelolactone Regulates Lipid Metabolism and Improves Hepatic Steatosis Partly by AMPK Activation and Up-Regulation of Expression of PPARα/LPL and LDLR. PLoS One (2015) 0.75
Treatment of infective hepatitis: Where biomedicine has no answers, Ayurveda has!! Anc Sci Life (2016) 0.75
Gallic acid decreases hepatitis C virus expression through its antioxidant capacity. Exp Ther Med (2015) 0.75
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
The price of innovation: new estimates of drug development costs. J Health Econ (2003) 23.43
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Qinghaosu (artemisinin): an antimalarial drug from China. Science (1985) 4.95
A mechanism for initiating RNA-dependent RNA polymerization. Nature (2001) 3.99
Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine (2009) 2.56
Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A (2010) 1.67
Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ (2004) 1.54
Cell-free replication of the hepatitis C virus subgenomic replicon. J Virol (2002) 1.52
Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol (2009) 1.43
In vivo hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves. Indian J Physiol Pharmacol (2001) 1.29
The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif (2006) 1.20
Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs (2007) 1.18
Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis (2011) 1.14
Eclipta alba extract with potential for hair growth promoting activity. J Ethnopharmacol (2009) 1.10
Suppression of hepatitis C virus replicon by TGF-beta. Virology (2005) 1.05
Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res (2008) 1.04
Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Antiviral Res (1996) 0.99
The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J Virol (2008) 0.98
Characterization of the metal ion binding properties of the hepatitis C virus RNA polymerase. J Biol Chem (2002) 0.98
Inhibition of snake venoms and phospholipases A(2) by extracts from native and genetically modified Eclipta alba: isolation of active coumestans. Basic Clin Pharmacol Toxicol (2009) 0.97
Development of the system ensuring a high-level expression of hepatitis C virus nonstructural NS5B and NS5A proteins. Protein Expr Purif (2006) 0.97
Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis (2011) 0.91
Inhibition of topoisomerase IIα: novel function of wedelolactone. Cancer Lett (2011) 0.90
Conformational dynamics of DnaB helicase upon DNA and nucleotide binding: analysis by intrinsic tryptophan fluorescence quenching. Biochemistry (2003) 0.87
On the determination of availability of ligand binding sites in steady-state systems. J Theor Biol (1977) 0.86
Structure-activity relationship of wedelolactone analogues: structural requirements for inhibition of Na+, K+ -ATPase and binding to the central benzodiazepine receptor. Bioorg Med Chem (2006) 0.86
Anti-HCV bioactivity of pseudoguaianolides from Parthenium hispitum. J Nat Prod (2007) 0.79
Identification of cellular factors associated with the 3'-nontranslated region of the hepatitis C virus genome. Mol Cell Proteomics (2006) 1.21
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 1.03
Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res (2005) 0.98
The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J Virol (2008) 0.98
A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology (2005) 0.90
A peptide nucleic acid-neamine conjugate that targets and cleaves HIV-1 TAR RNA inhibits viral replication. J Med Chem (2004) 0.89
Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome. Virology (2007) 0.89
Affinity capture and identification of host cell factors associated with hepatitis C virus (+) strand subgenomic RNA. Mol Cell Proteomics (2013) 0.88
Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice. Oligonucleotides (2008) 0.88
Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem (2002) 0.87
STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Mol Cancer Ther (2008) 0.86
Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog. Antiviral Res (2002) 0.86
Mechanism of RNA cleavage catalyzed by sequence specific polyamide nucleic acid-neamine conjugate. Oligonucleotides (2007) 0.86
PNA targeting the PBS and A-loop sequences of HIV-1 genome destabilizes packaged tRNA3(Lys) in the virions and inhibits HIV-1 replication. Virology (2002) 0.83
Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket. Biochemistry (2002) 0.83
An efficient biodelivery system for antisense polyamide nucleic acid (PNA). Oligonucleotides (2008) 0.82
A single deletion at position 134, 135, or 136 in the beta 7-beta 8 loop of the p51 subunit of HIV-1 RT disrupts the formation of heterodimeric enzyme. J Cell Biochem (2010) 0.81
Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome. Oligonucleotides (2008) 0.81
A positively charged side chain at position 154 on the beta8-alphaE loop of HIV-1 RT is required for stable ternary complex formation. Nucleic Acids Res (2003) 0.79
Impact of template overhang-binding region of HIV-1 RT on the binding and orientation of the duplex region of the template-primer. Mol Cell Biochem (2009) 0.78
Inhibition of HIV Replication by Cyclic and Hairpin PNAs Targeting the HIV-1 TAR RNA Loop. J Nucleic Acids (2012) 0.77
Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site. Biochemistry (2013) 0.77
The glutamine side chain at position 91 on the β5a-β5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket. Biochemistry (2011) 0.77
Influence of the RNase H domain of retroviral reverse transcriptases on the metal specificity and substrate selection of their polymerase domains. Virol J (2009) 0.76
Tracheobronchial compression by right-sided aortic arch in a middle aged male. Indian J Chest Dis Allied Sci (2012) 0.75